| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PROZ |
| Uniprot No | P22891 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-400aa |
| 氨基酸序列 | AGSYLLEELF EGNLEKECYE EICVYEEARE VFENEVVTDE FWRRYKGGSP CISQPCLHNG SCQDSIWGYT CTCSPGYEGS NCELAKNECH PERTDGCQHF CLPGQESYTC SCAQGYRLGE DHKQCVPHDQ CACGVLTSEK RAPDLQDLPW QVKLTNSEGK DFCGGVIIRE NFVLTTAKCS LLHRNITVKT YFNRTSQDPL MIKITHVHVH MRYDADAGEN DLSLLELEWP IQCPGAGLPV CTPEKDFAEH LLIPRTRGLL SGWARNGTDL GNSLTTRPVT LVEGEECGQV LNVTVTTRTY CERSSVAAMH WMDGSVVTRE HRGSWFLTGV LGSQPVGGQA HMVLVTKVSR YSLWFKQIMN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PROZ重组蛋白的模拟参考文献示例(仅供学术写作参考，建议通过PubMed或Google Scholar获取真实文献)：
---
1. **文献名称**: "High-yield expression and purification of recombinant human Protein Z in Escherichia coli"
**作者**: Zhang L, et al.
**摘要**: 该研究报道了在大肠杆菌中高效表达重组人Protein Z的优化方法，采用His标签纯化技术，获得高纯度蛋白，并验证其与磷脂表面的结合活性，为凝血研究提供工具。
2. **文献名称**: "Functional characterization of Protein Z-dependent protease inhibitor (ZPI) interaction using recombinant PROZ variants"
**作者**: Smith JR, et al.
**摘要**: 通过构建重组PROZ突变体，揭示了Protein Z与ZPI结合的关键结构域，证明其在抑制凝血因子Xa中的作用，为遗传性凝血缺陷的机制研究提供依据。
3. **文献名称**: "Recombinant Protein Z as a potential biomarker for thrombotic risk assessment"
**作者**: Gupta S, et al.
**摘要**: 探索重组PROZ作为血栓风险生物标志物的临床应用，通过ELISA检测患者血浆中Protein Z水平，发现其与静脉血栓形成的负相关性。
---
**备注**：以上为模拟示例，实际文献需通过学术数据库查询。研究PROZ重组蛋白时，可关注其凝血调节功能、结构-功能关系及临床转化方向。
PROZ (Protein Z) is a vitamin K-dependent glycoprotein primarily synthesized in the liver, playing a regulatory role in coagulation. Discovered in 1984. it acts as a cofactor for the inhibition of activated coagulation factor X (FXa) by enhancing the activity of its endogenous inhibitor, protein Z-dependent protease inhibitor (ZPI). Structurally, PROZ consists of an N-terminal γ-carboxyglutamic acid (Gla) domain critical for calcium-dependent phospholipid binding, two epidermal growth factor (EGF)-like domains, and a C-terminal protease-like domain. Its gene, located on chromosome 13 in humans, spans eight exons.
Recombinant PROZ is produced using biotechnological platforms such as mammalian cell expression systems (e.g., HEK293 or CHO cells) or bacterial systems, enabling large-scale production with high purity and consistency. This engineered protein retains the functional properties of native PROZ, making it valuable for research and therapeutic applications. Researchers utilize recombinant PROZ to investigate coagulation disorders, including unexplained thrombophilias or hemorrhagic conditions linked to PROZ deficiency. It also serves as a tool for developing diagnostic assays and studying interactions with ZPI in regulating hemostatic balance.
Beyond basic research, recombinant PROZ holds potential in drug development, particularly for conditions involving dysregulated coagulation. Its role in modulating FXa activity positions it as a candidate for novel anticoagulant therapies. However, the protein's pleiotropic effects—including debated associations with inflammatory and vascular pathologies—warrant further mechanistic studies. Current applications emphasize its utility in dissecting coagulation pathways, while ongoing research explores its broader physiological impacts and therapeutic targeting opportunities.
×
